Drug Trial Radar · NCT03694353
Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU
Last checked: Nov 20, 2026Latest source record: Feb 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Sep 13, 2018
Primary completion
Jan 13, 2021
Study completion Jan 13, 2021
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Oct 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 open-label extension study enrolling adult patients with PKU who were previously treated with pegvaliase in Studies PAL-003 (NCT00924703) or 165-302 (NCT02468570). The study is designed to evaluate the long-term safety and efficacy of pegvaliase administered at doses \> 40 mg/day to 60 mg/day.
Conditions
- Phenylketonuria (PKU)
Interventions
PegvaliaseDrug
40-60mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0Time frame: Up to Day 741 (approximately Week 106)
- Change in Blood Phe ConcentrationTime frame: The Outcome Measure Data Table below uses the 'analysis visit' as defined by the mapping rule in the SAP. The last Phe measurement was mapped to 'analysis visit' week 121. The actual date of the last Phe measurement was day 836 (approximately Week 119).
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of Florida
Gainesville, Florida
University of South Florida
Tampa, Florida
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Indiana CTSI Clinical Research Center
Indianapolis, Indiana
University of Kentucky Medical Center
Lexington, Kentucky
Wayne State University, Center for Molecular Medicine and Genetics, Pediatrics and Pathology
Detroit, Michigan
University of Missouri Health Care
Columbia, Missouri
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Morristown Medical Center
Morristown, New Jersey
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma
Oregon Health and Science University
Portland, Oregon
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Health Science Center at Houston
Houston, Texas
Medical College of Milwaukee
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.